SAN DIEGO, Feb. 02, 2023 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) as we speak posted a complement to its beforehand issued “Ceaselessly Requested Questions” doc beneath the “Traders” part of its...
Read More
15 Minutes